Skip to main content

IMI impact on antimicrobial resistance

Combatting antimicrobial resistance: the legacy of the IMI COMBACTE projects

Illustration of antimicrobial resistance. Image credit: nobeastsofierce via Shutterstock
Illustration of antimicrobial resistance. Image credit: nobeastsofierce via Shutterstock

About antimicrobial resistance and the COMBACTE projects

Antimicrobial resistance is considered to be one of the top global public health and development threats, and it's estimated to cause more than 35 000 deaths per year in the EU. Despite this, few new antibiotics make it onto the market, meaning that there is an urgent need for innovative antimicrobials to treat resistant infections.

The COMBACTE projects - COMBACTE-NET, COMBACTE-MAGNET and COMBACTE-CARE formed public-private partnerships with the goal of addressing the challenges of clinical development of antibacterial medicines in response to antibiotic resistance. COMBACTE-NET focused on building strong clinical, laboratory and research networks to boost efficiency in testing new antibacterial agents; COMBACTE-MAGNET investigated the needs of critically-ill patients to develop better targeted treatments; and COMBACTE-CARE laid the foundations for the development of novel treatments against multi-drug resistant bacteria. This online webinar will highlight the impact that the COMBACTE projects are having in tackling antibiotic-resistant bacteria.

The COMBACTE projects are part of IMI's New Drugs for Bad Bugs programme, which comprises several projects that are finding solutions to the scientific, regulatory, and business challenges that are hampering the development of new antibiotics.


Meet the speakers
Marc Bonten

Professor of Infection and Immunity, UMC Utrecht

and Chief Executive Officer, Ecraid

Jesús Rodríguez Baño

Professor of Medicine, Infectious Diseases Division

Hospital Universitario Virgen Macarena, University of Sevilla and Instituto of Biomedicine of Sevilla

Halley Rogers

Director of Clinical Research


Bruno François

Doctor of Medicine and COMBACTE-NET Academic Lead

CHU Limoges

Hasan Jafri

Chief Medical Officer and Head of Clinical Development

Aridis Pharmaceuticals

Nathalie Seigneuret

Senior scientific officer
Event moderator

Innovative Health Initiative